Sugi Predict

Sugi Predict / Compounds / SCHEMBL565717

SCHEMBL565717

SCHEMBL565717

COc1ccc(Br)c(C=O)c1F

nearest known ligand 0.64

Predicted protein targets (top 15)

geneUniProtsupporting neighboursconfidence
▸ ERN1 O75460 8/20 0.64
▸ PRKDC P78527 1/20 0.47
▸ ALDH1A1 P00352 6/20 0.40
▸ MAPT P10636 3/20 0.40
▸ TSHR P16473 1/20 0.40
▸ SMN1; SMN2 Q16637 2/20 0.39
▸ LMNA P02545 1/20 0.39
▸ HPGD P15428 1/20 0.39
▸ L3MBTL1 Q9Y468 1/20 0.39
▸ AMY1A P0DUB6 1/20 0.38
▸ KDM4E B2RXH2 1/20 0.38
▸ AOX1 Q06278 1/20 0.37
▸ NPC1 O15118 1/20 0.36
▸ HTT P42858 1/20 0.36
▸ RAB9A P51151 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30988820 0.88 ERN1 (0.50) ERN1PRKDCALDH1A1MAPTTSHR
SCHEMBL30853338 0.85 ERN1 (0.59) ERN1PRKDCALDH1A1MAPTTSHR
SCHEMBL276550 0.85 ERN1 (0.59) ERN1PRKDCALDH1A1MAPTTSHR
SCHEMBL1478225 0.84 ERN1 (0.47) ERN1PRKDCALDH1A1TSHRKDM4E
SCHEMBL2240164 0.82 ERN1 (0.47) ERN1PRKDCALDH1A1MAPTSMN1; SMN2
SCHEMBL24738001 0.81 ERN1 (0.46) ERN1PRKDCALDH1A1MAPTAMY1A
SCHEMBL953686 0.81 ERN1 (0.44) ERN1PRKDCALDH1A1TSHRLMNA
SCHEMBL25286856 0.81 ERN1 (0.68) ERN1PRKDCALDH1A1MAPTTSHR
SCHEMBL10019788 0.81 LMNA (0.51) ERN1ALDH1A1MAPTTSHRSMN1; SMN2
SCHEMBL20652789 0.80 ERN1 (0.45) ERN1PRKDC

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 142 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4735425-A1 COMPOUNDS Psylo Pty Ltd (AU) 2026-05-06 — — EP disclosed
US-20250353874-A1 GLUCOCORTICOID RECEPTOR AGONISTS LILLY CO ELI (US) 2025-11-20 — — US disclosed
US-20250353818-A1 Compounds Psylo Pty Ltd (AU) 2025-11-20 — — US disclosed
US-12428380-B2 Compounds Psylo Pty Ltd (AU) 2025-09-30 — — US disclosed
US-12404298-B2 Glucocorticoid receptor agonists ELI LILLY AND COMPANY (US) 2025-09-02 — — US disclosed
EP-4585265-A2 HETEROARYL INHIBITORS OF PLASMA KALLIKREIN Takeda Pharmaceutical Company Limited (JP) 2025-07-16 — — EP disclosed
US-20250214943-A1 Compounds Psylo Pty Ltd (AU) 2025-07-03 — — US disclosed
EP-4543924-A2 HUMAN CD33 ANTIBODIES AND GLUCOCORTICOID CONJUGATES ELI LILLY AND COMPANY (US) 2025-04-30 — — EP disclosed
US-12281057-B2 Carboxamides as modulators of sodium channels VERTEX PHARMACEUTICALS INCORPORATED (US) 2025-04-22 — — US disclosed
CN-119744180-A Human tumor necrosis factor alpha antibody glucocorticoid conjugate 伊莱利利公司 2025-04-01 — — CN disclosed
US-20090291917-A1 Boron-Containing Small Molecules as Anti-Inflammatory Agents ANACOR PHARMACEUTICALS, INC. (US) 2009-11-26 — — US disclosed
WO-2009111676-A2 BORON-CONTAINING SMALL MOLECULES AS ANTI-INFLAMMATORY AGENTS ANACOR PHARMACEUTICALS, INC (US) 2009-09-11 — — WO disclosed
WO-2009111676-A2 BORON-CONTAINING SMALL MOLECULES AS ANTI-INFLAMMATORY AGENTS ANACOR PHARMACEUTICALS, INC (US) 2009-09-11 — — WO disclosed
US-20090197908-A1 Benzocycloheptapyridines as inhibitors of the receptor tyrosine kinase met MERCK SHARP & DOHME LLC 2009-08-06 — — US disclosed
US-7550478-B2 Tyrosine kinase inhibitors MERCK & CO. INC. (US) 2009-06-23 — — US disclosed
EP-1896421-A2 BENZOCYCLOHEPTAPYRIDINES AS INHIBITORS OF THE RECEPTOR TYROSINE KINASE MET Merck & Co., Inc. (US) 2008-03-12 — — EP disclosed
US-20070225308-A1 2-Amino Quinazoline Derivative KYOWA HAKKO KOGYO CO.,LTD. (JP) 2007-09-27 — — US disclosed
WO-2007002254-A2 BENZOCYCLOHEPTAPYRIDINES AS INHIBITORS OF THE RECEPTOR TYROSINE KINASE MET MERCK & CO., INC. (US) 2007-01-04 — — WO disclosed
US-20060293358-A1 Tyrosine kinase inhibitors MERCK SHARP & DOHME LLC 2006-12-28 — — US disclosed
EP-1726584-A1 2-AMINOQUINAZOLINE DERIVATIVE KYOWA HAKKO KOGYO CO., LTD. (JP) 2006-11-29 — — EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (10 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070225308-A1 2-Amino Quinazoline Derivative AGTR2, ABL1, AGTR1 ERN1 3874/4885PRKDC 4703/4885ALDH1A1 1519/4885
US-20250214943-A1 Compounds NLN, SLC18A2, PYGB ERN1 2714/4885PRKDC 3452/4885ALDH1A1 981/4885
US-12404298-B2 Glucocorticoid receptor agonists NR3C1, NR3C2, MC2R ERN1 1650/4885PRKDC 1116/4885ALDH1A1 3227/4885
US-20250353874-A1 GLUCOCORTICOID RECEPTOR AGONISTS NR3C1, NR3C2, MC2R ERN1 1650/4885PRKDC 1116/4885ALDH1A1 3227/4885
US-20090291917-A1 Boron-Containing Small Molecules as Anti-Inflammatory Agents NFKBIA, LITAF, CD68 ERN1 1887/4885PRKDC 3894/4885ALDH1A1 3761/4885
US-12428380-B2 Compounds NLN, SLC18A2, PYGB ERN1 2714/4885PRKDC 3452/4885ALDH1A1 981/4885
US-20250353818-A1 Compounds NLN, SLC18A2, PYGB ERN1 2714/4885PRKDC 3452/4885ALDH1A1 981/4885
US-20060293358-A1 Tyrosine kinase inhibitors ABL1, ERBB2, RET ERN1 3040/4885PRKDC 209/4885ALDH1A1 1039/4885
US-20090197908-A1 Benzocycloheptapyridines as inhibitors of the receptor tyrosine kinase met MET, RET, ERBB2 ERN1 3520/4885PRKDC 620/4885ALDH1A1 632/4885
US-12281057-B2 Carboxamides as modulators of sodium channels TRPV1, SCN2A, SCN10A ERN1 2993/4885PRKDC 3348/4885ALDH1A1 2665/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.